Experimental drug BNC210 shows early benefits in PTSD trial
Bionomics Limited is reporting that their experimental drug BNC210, a novel α7 nicotinic acetylcholine receptor modulator, significantly reduced symptom severity in patients with post-traumatic stress disorder (PTSD).